intravenous antibiotics Cefepime-enmetazobactam may be more effective than piperacillin-tazobactam in treating complicated UTI and acute pyelonephritis caused by organisms that produce ...

For adults with complicated urinary tract infection (UTI), including acute pyelonephritis, cefepime-taniborbactam is superior to meropenem, according to a study published in the Feb. 15 issue of the ...

Cefepime-taniborbactam has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation by the U.S. Food and Drug Administration (FDA). In October 2022, BARDA awarded a contract ...

Please provide your email address to receive an email when new articles are posted on . McGovern PC, et al. Abstract 731. Presented at: IDWeek; Oct. 19- 23, 2022. Washington (hybrid meeting). A ...

About The Study: Among 2,511 adults hospitalized with acute infection, treatment with the antibiotic piperacillin-tazobactam did not increase the incidence of acute kidney injury or death in this ...

In patients with complicated urinary tract infection, clinical and microbiologic treatment success was significantly better with cefepime–taniborbactam (β-lactam and β-lactamase inhibitor) than with ...

The frequency of neutropenia in patients receiving long-term cefepime therapy for osteomyelitis compared with that in patients receiving other antimicrobials was studied. A comparative case review was ...

Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...

For complicated urinary tract infection, the efficacy and safety of the investigational cefepime–taniborbactam combination, in comparison with standard treatment with meropenem, are unknown. New ...